GILEAD SCIENCES TO BUY KITE PHARMA FOR $11.9B
Gilead Sciences, a cancer-drug maker, agreed Monday to pay about $11.9 billion in cash, or about $180 per share, to buy Kite Pharma, a move to expand its product lineup in cancer immunotherapies.
Gilead Sciences, a cancer-drug maker, agreed Monday to pay about $11.9 billion in cash, or about $180 per share, to buy Kite Pharma, a move to expand its product lineup in cancer immunotherapies.